Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: This study aimed to assess the screening properties of Foderaro et al.s' updated normative framework for the Italian MMSE in detecting mild cognitive impairment (MCI) and dementia due to neurodegenerative, chronic cerebrovascular, and mixed etiologies, as well as in differentiating between these two syndromes.

Methods: Data on 234 patients with either MCI (N = 83) or dementia (N = 151) due to Alzheimer's disease (N = 112), Lewy body disease (N = 11), frontotemporal lobar degeneration (N = 20), chronic cerebrovascular disease (N = 39), or mixed (N = 47) etiologies having been administered Foderaro et al.'s version of the MMSE were retrospectively recruited. Moreover, N = 247 healthy controls (HCs) with a normal Montreal Cognitive Assessment performance were prospectively recruited. Receiver-operating characteristics analyses were run to test the capability of both raw and demographically adjusted MMSE scores to discriminate both HCs from MCI/dementia and MCI from dementia. For these comparisons, screening metrics were also computed at Foderaro et al.'s cut-off (<26.02).

Results: The capability of demographically adjusted MMSE scores to discriminate both HCs from dementia and MCI from dementia was excellent (AUC = 0.91 and 0.93, respectively), whilst good for MCI case-finding (AUC = 0.85). Consistently, the screening metrics associated with the cut-off at hand were optimal-to-excellent for dementia case-finding (sensitivity = 0.95; specificity = 0.99) and for the differentiation between MCI and dementia (sensitivity = 0.95; specificity = 0.64), whilst imbalanced for detecting MCI (sensitivity = 0.35; specificity = 0.99).

Discussion: Foderaro et al.'s updated normative framework for the Italian MMSE has optimal screening properties for both dementia case-finding and the discrimination between MCI and dementia, being at variance unbalanced towards specificity when it comes to detecting MCI.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10072-024-07952-4DOI Listing

Publication Analysis

Top Keywords

mci dementia
12
screening properties
8
updated normative
8
normative framework
8
framework italian
8
italian mmse
8
chronic cerebrovascular
8
foderaro al's
8
properties updated
4
mmse
4

Similar Publications

Evidence suggests that working memory (WM) capacity decreases with age, resulting in cognitive decline. Given the link between aging and reduced hippocampal volume, this study examined whether and how hippocampal volume is associated with WM. 46 participants aged 65-85 years (Mage = 71.

View Article and Find Full Text PDF

Background: Plasma p-tau181 has proven to be a promising diagnostic and prognostic tool in the earliest phases of Alzheimer's disease (AD). We aimed to evaluate the prognostic role of p-tau181 in predicting conversion to AD dementia and worsening in cognition in mild cognitive impairment (MCI) and subjective cognitive decline (SCD).

Methods: We consecutively enrolled 163 patients (50 SCD, 70 MCI, and 43 AD-demented (AD-d)), who underwent plasma p-tau181 analysis with the Simoa assay.

View Article and Find Full Text PDF

Objectives: This study investigated the longitudinal relationship between participation in Cognitively Stimulating Leisure Activities (CSLAs) and the risk of Alzheimer's Disease and Related Dementias (ADRD) in two different groups of older adults with and without Mild Cognitive Impairment (MCI).

Methods: We analyzed data from the Health and Retirement Study, a nationally representative survey of adults in the United States from 2012 to 2020 (MCI = 14,280; without MCI = 13,695) using a Generalized Estimated Equation. The Telephone Interview for Cognitive Status-27 was used to identify samples with MCI, with scores ranging from 7 to 11.

View Article and Find Full Text PDF

Introduction: Mild cognitive impairment (MCI) represents a transitional stage between normal aging and dementia. We investigate associations among cardiovascular and metabolic disorders (hypertension, diabetes mellitus, and hyperlipidemia) and diagnosis (normal; amnestic [aMCI]; and non-amnestic [naMCI]).

Methods: Multinomial logistic regressions of participant data (N = 8737; age = 70.

View Article and Find Full Text PDF

Use of a Screening Tool for Dementia in a Down Syndrome Specialty Clinic.

Am J Med Genet A

September 2025

Down Syndrome Program, Division of Medical Genetics and Metabolism, Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA.

To study the use of a dementia screening tool in our clinic cohort of adults with Down syndrome. To evaluate the functionality of the NTG-EDSD for Dementia as part of a dementia screening protocol for adults with Down syndrome, we conducted a cohort analysis of patients aged 40 and older followed at the Massachusetts General Hospital Down Syndrome Program, noting any clinical interpretation of dementia or mild cognitive impairment (MCI). From September 2023 to September 2024, 54 NTG-EDSD responses were collected.

View Article and Find Full Text PDF